Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tancini

Showing results (191-200 of 218) with videos related to

Pageof 22
Sort By:
La Radiologia Medica|October 1, 1987
[Concomitant therapy with cisplatin and radiotherapy in locally advanced tumors of the cervico-facial area]A Colombo, S Crispino, S Barni, et al.
Oncology|January 1, 1992
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatinP Lissoni, S Barni, A Ardizzoia, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|April 1, 1995
[Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma]M G Viganò, P Lissoni, S Barni, et al.
Tumori|December 31, 1992
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinomaS Barni, P Lissoni, M Cazzaniga, et al.
Journal of Biological Regulators and Homeostatic Agents|July 1, 1993
Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patientsS Crispino, P Lissoni, A Ardizzoia, et al.
Cancer|March 15, 1993
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2P Lissoni, S Pittalis, F Brivio, et al.
Tumori|October 31, 1987
Clinical study of melatonin in untreatable advanced cancer patientsP Lissoni, S Barni, G Tancini, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1995
Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II studyP Lissoni, L Vigorè, R Rescaldani, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinomaR Aldeghi, P Lissoni, S Barni, et al.
Journal of Biological Regulators and Homeostatic Agents|July 1, 1992
Tumor necrosis factor in solid tumors: increased blood levels in the metastatic diseaseA Ardizzoia, P Lissoni, F Brivio, et al.
Pageof 22

Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
La Radiologia Medica|October 1, 1987
[Concomitant therapy with cisplatin and radiotherapy in locally advanced tumors of the cervico-facial area]A Colombo, S Crispino, S Barni, et al.
Oncology|January 1, 1992
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatinP Lissoni, S Barni, A Ardizzoia, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|April 1, 1995
[Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma]M G Viganò, P Lissoni, S Barni, et al.
Tumori|December 31, 1992
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinomaS Barni, P Lissoni, M Cazzaniga, et al.
Journal of Biological Regulators and Homeostatic Agents|July 1, 1993
Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patientsS Crispino, P Lissoni, A Ardizzoia, et al.
Cancer|March 15, 1993
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2P Lissoni, S Pittalis, F Brivio, et al.
Tumori|October 31, 1987
Clinical study of melatonin in untreatable advanced cancer patientsP Lissoni, S Barni, G Tancini, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1995
Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II studyP Lissoni, L Vigorè, R Rescaldani, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinomaR Aldeghi, P Lissoni, S Barni, et al.
Journal of Biological Regulators and Homeostatic Agents|July 1, 1992
Tumor necrosis factor in solid tumors: increased blood levels in the metastatic diseaseA Ardizzoia, P Lissoni, F Brivio, et al.
Pageof 22